Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 58 Pages
|Vectibix(大腸癌症):市場預測與分析 Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023|
|出版日期: 2014年11月28日||內容資訊: 英文 58 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.
Amgen/Takeda's EGFR antagonist Vectibix (panitumumab) was approved in the US in 2006 as a monotherapy for chemotherapy-refractory, EGFR-expressing, KRAS wild-type metastatic CRC. EU approval followed in 2007, where the agent is also indicated as a treatment for chemotherapy-refractory KRAS wild-type CRC patients, however, EGFR-expression is not specified. Additionally in the EU, the antibody is approved in combination with FOLFOX in the first-line setting, and with FOLFIRI in the second-line setting after progression on a 5-FU regimen. In April 2014, the EU label for Vectibix was updated to specify RAS wild-type disease rather than KRAS.